DK1706121T3 - Dk/ep - Google Patents

Dk/ep

Info

Publication number
DK1706121T3
DK1706121T3 DK05701469T DK05701469T DK1706121T3 DK 1706121 T3 DK1706121 T3 DK 1706121T3 DK 05701469 T DK05701469 T DK 05701469T DK 05701469 T DK05701469 T DK 05701469T DK 1706121 T3 DK1706121 T3 DK 1706121T3
Authority
DK
Denmark
Prior art keywords
compounds
endopeptidase
hsep
benzoxazepine
benzothiazepine
Prior art date
Application number
DK05701469T
Other languages
Danish (da)
English (en)
Inventor
Michael Weske
Lechoslaw A Turski
Hrissanthi Ikonomidou
Dieter Ziegler
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1706121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of DK1706121T3 publication Critical patent/DK1706121T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK05701469T 2004-01-12 2005-01-10 Dk/ep DK1706121T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53553804P 2004-01-12 2004-01-12
EP04100067 2004-01-12
PCT/EP2005/050075 WO2005067937A1 (en) 2004-01-12 2005-01-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
DK1706121T3 true DK1706121T3 (da) 2009-01-05

Family

ID=34796705

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05701469T DK1706121T3 (da) 2004-01-12 2005-01-10 Dk/ep

Country Status (22)

Country Link
EP (1) EP1706121B1 (ja)
JP (1) JP4951350B2 (ja)
KR (1) KR101219580B1 (ja)
CN (1) CN101076339B (ja)
AT (1) ATE406899T1 (ja)
AU (1) AU2005205067B2 (ja)
BR (1) BRPI0506750A (ja)
CA (1) CA2551789C (ja)
CY (1) CY1108588T1 (ja)
DE (1) DE602005009487D1 (ja)
DK (1) DK1706121T3 (ja)
ES (1) ES2313279T3 (ja)
HR (1) HRP20080611T3 (ja)
IL (1) IL176456A (ja)
NO (1) NO20063623L (ja)
PL (1) PL1706121T3 (ja)
PT (1) PT1706121E (ja)
RU (1) RU2362563C2 (ja)
SI (1) SI1706121T1 (ja)
UA (1) UA82008C2 (ja)
WO (1) WO2005067937A1 (ja)
ZA (1) ZA200605549B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750510A1 (en) * 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
CN110590695B (zh) * 2019-10-22 2023-03-21 南华大学 苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1297453A (zh) * 1998-04-23 2001-05-30 诺瓦提斯公司 硫醇类内皮缩血管肽转化酶抑制剂
US20020013307A1 (en) * 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) * 2001-03-13 2003-01-07 Micro Motion, Inc. Initialization algorithm for drive control in a coriolis flowmeter
AR039352A1 (es) * 2001-05-18 2005-02-16 Solvay Pharm Gmbh Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Also Published As

Publication number Publication date
CN101076339A (zh) 2007-11-21
BRPI0506750A (pt) 2007-05-22
IL176456A0 (en) 2006-10-05
EP1706121A1 (en) 2006-10-04
RU2006129288A (ru) 2008-02-20
AU2005205067B2 (en) 2009-10-22
JP2007517834A (ja) 2007-07-05
HRP20080611T3 (en) 2008-12-31
ATE406899T1 (de) 2008-09-15
WO2005067937A1 (en) 2005-07-28
CN101076339B (zh) 2011-02-09
EP1706121B1 (en) 2008-09-03
PT1706121E (pt) 2008-12-04
RU2362563C2 (ru) 2009-07-27
UA82008C2 (uk) 2008-02-25
KR101219580B1 (ko) 2013-01-08
CY1108588T1 (el) 2014-04-09
KR20060123541A (ko) 2006-12-01
ZA200605549B (en) 2007-12-27
IL176456A (en) 2010-03-28
SI1706121T1 (sl) 2009-02-28
CA2551789A1 (en) 2005-07-28
PL1706121T3 (pl) 2009-02-27
NO20063623L (no) 2006-10-12
ES2313279T3 (es) 2009-03-01
AU2005205067A1 (en) 2005-07-28
JP4951350B2 (ja) 2012-06-13
DE602005009487D1 (de) 2008-10-16
CA2551789C (en) 2011-05-03

Similar Documents

Publication Publication Date Title
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
GEP20125565B (en) Lactam compounds and their pharmaceutical use
WO2008079291A3 (en) Substituted heterocycles and methods of use
WO2005070891A3 (en) Compounds and methods of use
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
WO2005066163A3 (en) Thiophene derivatives as chk 1 inihibitors
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
IN2012DN03043A (ja)
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
HRP20080611T3 (en) Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2007072092A8 (en) New phenanthridine derivatives as bradykinin antagonists
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2005055943A3 (en) Vinorelbine derivatives
WO2008033935A3 (en) Vinorelbine derivatives
WO2006041888A3 (en) Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
GB0407025D0 (en) Novel compounds
WO2008113756A8 (en) Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors